Jenburkt [JENBURPH] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison

Jenburkt Pharmaceuticals Ltd.

BSE
Loading...

Divi's Laboratories Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Jenburkt Pharmaceuticals Ltd. wins in 9 metrics, Divi's Laboratories Ltd. wins in 11 metrics, with 0 ties. Divi's Laboratories Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Jenburkt Pharmaceuticals Ltd. Divi's Laboratories Ltd. Better
P/E Ratio (TTM) 14.42 67.11 Jenburkt Pharmaceuticals Ltd.
Price-to-Book Ratio 2.56 10.82 Jenburkt Pharmaceuticals Ltd.
Debt-to-Equity Ratio 0.93 0.58 Divi's Laboratories Ltd.
PEG Ratio -0.38 4.63 Divi's Laboratories Ltd.
EV/EBITDA 11.57 48.63 Jenburkt Pharmaceuticals Ltd.
Profit Margin (TTM) 19.63% 24.04% Divi's Laboratories Ltd.
Operating Margin (TTM) 15.33% 29.65% Divi's Laboratories Ltd.
EBITDA Margin (TTM) 15.33% 29.65% Divi's Laboratories Ltd.
Return on Equity 18.66% 14.64% Jenburkt Pharmaceuticals Ltd.
Return on Assets (TTM) 16.34% 12.94% Jenburkt Pharmaceuticals Ltd.
Free Cash Flow (TTM) $81.92M $2.15B Divi's Laboratories Ltd.
Dividend Yield 2.48% 0.91% Jenburkt Pharmaceuticals Ltd.
1-Year Return -10.00% -0.43% Divi's Laboratories Ltd.
Price-to-Sales Ratio (TTM) 2.83 16.18 Jenburkt Pharmaceuticals Ltd.
Enterprise Value $4.59B $1,635.46B Divi's Laboratories Ltd.
EV/Revenue Ratio 2.78 15.86 Jenburkt Pharmaceuticals Ltd.
Gross Profit Margin (TTM) 79.57% 63.71% Jenburkt Pharmaceuticals Ltd.
Revenue per Share (TTM) $374 $388 Divi's Laboratories Ltd.
Earnings per Share (Diluted) $73.50 $93.66 Divi's Laboratories Ltd.
Beta (Stock Volatility) 0.33 0.19 Divi's Laboratories Ltd.

Jenburkt Pharmaceuticals Ltd. vs Divi's Laboratories Ltd. Stock Performance Analysis

Loading Price Chart...

JENBURPH
DIVISLAB

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Jenburkt Pharmaceuticals Ltd.-1.09%1.28%-2.09%15.56%6.36%6.69%
Divi's Laboratories Ltd.-0.44%1.34%-2.25%8.85%4.11%4.17%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Jenburkt Pharmaceuticals Ltd.-10.00%65.07%145.34%194.80%1,213.55%5,074.07%
Divi's Laboratories Ltd.-0.43%85.44%58.15%496.33%1,610.60%10,946.76%

Performance & Financial Health Analysis: Jenburkt Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

MetricJENBURPHDIVISLAB
Market Information
Market Cap i₹4.68B₹1.69T
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i1,043253,443
90 Day Avg. Volume i1,047283,911
Last Close₹1,174.55₹6,608.50
52 Week Range₹944.00 - ₹1,410.00₹5,636.50 - ₹7,071.50
% from 52W High-16.70%-6.55%
All-Time High₹1,410.00 (Jul 08, 2025)₹7,071.50 (Jul 08, 2025)
% from All-Time High-16.70%-6.55%
Growth Metrics
Quarterly Revenue Growth0.17%0.12%
Quarterly Earnings Growth-0.09%-0.01%
Financial Health
Profit Margin (TTM) i0.20%0.24%
Operating Margin (TTM) i0.15%0.30%
Return on Equity (TTM) i0.19%0.15%
Debt to Equity (MRQ) i0.930.58
Cash & Liquidity
Book Value per Share (MRQ)₹414.40₹580.95
Cash per Share (MRQ)₹21.86₹122.95
Operating Cash Flow (TTM) i₹252.79M₹19.67B
Levered Free Cash Flow (TTM) i₹320.61M₹21.91B
Dividends
Last 12-Month Dividend Yield i2.48%0.91%
Last 12-Month Dividend i₹33.30₹60.00

Valuation & Enterprise Metrics Analysis: Jenburkt Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

MetricJENBURPH (Apr 24, 2026)DIVISLAB (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i14.4267.11
Forward P/E i30.4153.75
PEG Ratio i-0.384.63
Price to Sales (TTM) i2.8316.18
Price to Book (MRQ) i2.5610.82
Market Capitalization
Market Capitalization i₹4.68B₹1.69T
Enterprise Value i₹4.59B₹1.64T
Enterprise Value Metrics
Enterprise to Revenue i2.7815.86
Enterprise to EBITDA i11.5748.63
Risk & Other Metrics
Beta i0.330.19
Book Value per Share (MRQ) i₹414.40₹580.95

Financial Statements Comparison: Jenburkt Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricJENBURPH (2025)DIVISLAB (2025)
Revenue/Sales i1.51B93.25B
Cost of Goods Sold i308.14M38.70B
COGS % of Revenue i20.4%41.5%
Gross Profit i1.21B54.55B
Gross Margin i79.6%58.5%
Research & Development i4.34M270.00M
Operating Income (EBIT) i376.79M25.71B
Operating Margin i24.9%27.6%
EBITDA i461.81M33.19B
EBITDA Margin i30.5%35.6%
Pre-Tax Income i439.33M29.16B
Pre-Tax Income % of Revenue i29.0%31.3%
Income Tax i118.72M7.25B
Income Tax % of Revenue i7.8%7.8%
Net Income (Profit) i320.61M21.91B
Profit Margin i21.2%23.5%

Balance Sheet & Liquidity Metrics

MetricJENBURPH (2025)DIVISLAB (2025)
Cash & Equivalents i73.65M4.15B
Total Current Assets i565.32M100.81B
Total Current Assets % of Revenue i37.3%108.1%
Total Current Liabilities i188.19M14.52B
Total Current Liabilities % of Revenue i12.4%15.6%
Long-Term Debt i14.92M20.00M
Long-Term Debt % of Revenue i1.0%0.0%
Total Shareholders Equity i1.72B149.69B
Retained Earnings i1.62B134.00B
Retained Earnings % of Revenue i107.3%143.7%
Property, Plant & Equipment i144.29M3.19B

Cash Flow Statement Comparison

MetricJENBURPH (2025)DIVISLAB (2025)
Operating Cash Flow i252.79M19.67B
Operating Cash Flow % of Revenue i16.7%21.1%
Capital Expenditures i-197.14M-14.38B
Free Cash Flow i81.92M2.15B
FCF Margin i5.4%2.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricJENBURPHDIVISLAB
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i4.41M265.47M
Float Shares i1.26M117.72M
% Held by Insiders i63.59%52.04%
% Held by Institutions i0.00%28.65%
% Held by Public i36.41%19.31%

Dividend Analysis & Yield Comparison: Jenburkt Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

MetricJENBURPHDIVISLAB
Last 12-Month Dividend i₹33.30₹60.00
Last 12-Month Dividend Yield i2.48%0.91%
3-Year Avg Annual Dividend i₹19.90₹50.00
3-Year Avg Dividend Yield i1.83%0.70%
3-Year Total Dividends i₹59.70₹150.00
Ex-Dividend DateJul 11, 2025Jul 25, 2025